Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pharmacoeconomics in heart failure: impact of drug and non-drug based treatment
Autore:
Cleland, JGF; Louis, A; Witte, K;
Indirizzi:
Univ Hull, Castle Hill Hosp, Dept Cardiol, Acad Unit, Kingston Upon Hull, Yorks, England Univ Hull Kingston Upon Hull Yorks England ton Upon Hull, Yorks, England
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: G, volume: 3, anno: 2001,
pagine: G25 - G32
SICI:
1520-765X(200107)3:G<G25:PIHFIO>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
MORTALITY; FUROSEMIDE; TORASEMIDE; PROGNOSIS; HOSPITALIZATION; EPIDEMIOLOGY; ENALAPRIL; MORBIDITY; THERAPY; DISEASE;
Keywords:
heart failure; pharmacoeconomics; diuretics; torasemide; furosemide; clinical outcome;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
32
Recensione:
Indirizzi per estratti:
Indirizzo: Cleland, JGF Univ Hull, Castle Hill Hosp, Dept Cardiol, Acad Unit, Kingston Upon Hull, Yorks, England Univ Hull Kingston Upon Hull Yorks England , Yorks, England
Citazione:
J.G.F. Cleland et al., "Pharmacoeconomics in heart failure: impact of drug and non-drug based treatment", EUR H J SUP, 3(G), 2001, pp. G25-G32

Abstract

Heart failure is a common and increasing problem associated with a high morbidity and mortality. The high morbidity of heart failure imposes the majority of costs of its treatment. Hospitalization among patients with heart failure is frequent, increasing, recurrent and often prolonged and constitutes about 65% of health spending on heart failure. A number of strategies can be envisaged to reduce recurrent heart failure hospitalization. ACE inhibitors (especially high-dose), beta-blockers, spironolactone and possibly digoxin, have all been shown to reduce substantially all-cause hospitalization in patients with heart failure in double-blind controlled trials. The most common single reason for re-admission is for worsening heart failure which may frequently be exacerbated by incomplete and unpredictable absorption of some diuretics. The loop diuretic, torasemide, because of its favourablepharmacokinetic and pharmacodynamic profile may be able to prevent worsening of underlying heart failure developing into a crisis, leading to hospitalization. Studies confirm that treatment with torasemide can reduce the rate of hospitalization due to worsening heart failure and is cost-effective. A stumbling block to progress that is often encountered is the unwillingness of budget holders to spend a small amount of money on better drugs and outpatient services in order to prevent hospitalization. This is exacerbated in many countries by a separate system for care of patients in and out of hospital. (Eur Heart J Supplements 2001; 3 (Suppl G): G25-G32) (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 14:43:47